

PRECEPTORSHIP PROGRAMME

Immuno-Oncology

From the essentials of tumour
immunology to clinical application

ZURICH
SWITZERLAND

2-3 NOVEMBER 2018

Co-Chairs John B.A.G. Haanen, NL
 Rolf A. Stahel, CH

ESMO PRECEPTORSHIP PROGRAMME

IMMUNO-ONCOLOGY

From the essentials of tumour immunology to clinical application

Zurich, Switzerland
2-3 November 2018

CO-CHAIRS:

John B.A.G. Haanen, Netherlands
Rolf A. Stahel, Switzerland

SPEAKERS:

Fabrice André, France	Pedro Romero, Switzerland
Andrés Cervantes, Spain	Patrick Roth, Switzerland
Alessandra Curioni, Switzerland	Cristiana Sessa, Switzerland
Mitchell Levesque, Switzerland	Lavinia Spain, United Kingdom
Markus G. Manz, Switzerland	Michiel S. van der Heijden, Netherlands
Bart Neyns, Belgium	

LEARNING OBJECTIVES

- To understand the basics of tumour immunology
- To learn about the essentials of immunotherapies and their applications in cancer medicine
- To learn about the status of development and clinical experience of immunotherapy in different tumour types

ACCREDITATION

The programme of this event has been accredited with **11 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



Bristol-Myers Squibb



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



Friday, 2 November 2018

09:00-09:15 15'	Historical introduction	
15'	Historical introduction	Rolf A. Stahel, CH
09:15-10:30 75'	SESSION 1 Essentials of tumour immunology	Chair: Rolf A. Stahel, CH
30'	From basic to tumour immunology for oncologists	Pedro Romero, CH
30'	From translational research to clinical application	John B.A.G. Haanen, NL
15'	Discussion	Faculty
10:30-11:00	Coffee break	
11:00-12:30 90'	SESSION 2 Essentials in immunotherapies	Chair: John B.A.G. Haanen, NL
25'	Immune Checkpoints - clinical use	Alessandra Curioni, CH
25'	Adoptive T-Cell transfer	John B.A.G. Haanen, NL
25'	Emerging concept of combination therapy	Alessandra Curioni, CH
15'	Discussion	Faculty
12:30-13:30	Lunch	
13:30-14:40 70'	SESSION 3 Clinical development	Chair: Rolf A. Stahel, CH
25'	Breast cancer	Fabrice André, FR
30'	Bladder and renal cell cancer	Michiel S. van der Heijden, NL
15'	Discussion	Faculty
14:40-15:20 40'	SESSION 4 Audience cases	Chair: Rolf A. Stahel, CH
40'	Participants clinical case discussion (4x10')	Faculty
15:20-15:50	Coffee break	
15:50-16:30 40'	SESSION 5 Clinical development	Chair: Rolf A. Stahel, CH
25'	Haemato-oncology	Markus G. Manz, CH
15'	Discussion	Faculty
16:30-17:10 40'	SESSION 6 Lung cancer and thoracic cancer - part 1	Chair: Rolf A. Stahel, CH
25'	Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer	Rolf A. Stahel, CH
15'	Discussion	Faculty

17:10-18:15 65'	SESSION 7 Clinical development	Chair: Andrés Cervantes, ES
25'	Immunotherapy of Gastro-Intestinal cancers	Andrés Cervantes, ES
25'	Gynaecological malignancies	Cristiana Sessa, CH
15'	Discussion	Faculty
19:30	Dinner	

Saturday, 3 November 2018

08:30-09:10 40'	SESSION 8 Audience cases	Chair: Andrés Cervantes, ES
40'	Participants clinical case discussion (4x10')	Faculty
09:10-10:15 65'	SESSION 9 Melanoma	Chair: Andrés Cervantes, ES
25'	Immune Checkpoints	Bart Neyns, BE
25'	Combination therapies	Bart Neyns, BE
15'	Discussion	Faculty
10:15-10:55 40'	SESSION 10 Immunomonitoring and tumour antigens	Chair: Rolf A. Stahel, CH
30'	Biomarkers for immunotherapy	Mitchell Levesque, CH
10'	Discussion	Faculty
10:55-11:20	Coffee break	
11:20-11:55 35'	SESSION 11 Lung cancer and thoracic cancer - part 2	Chair: Rolf A. Stahel, CH
25'	Immune Checkpoint Inhibitors in other thoracic malignancies	Rolf A. Stahel, CH
10'	Discussion	Faculty
11:55-12:30 35'	SESSION 12 Clinical development	Chair: Rolf A. Stahel, CH
25'	Glioblastoma	Patrick Roth, CH
10'	Discussion	Faculty
12:30-13:05 35'	SESSION 13 Trial design and management of toxicities	Chair: Rolf A. Stahel, CH
25'	Management of toxicities	Lavinia Spain, UK
10'	Discussion	Faculty
13:05-13:15 10'	General discussion	Rolf A. Stahel, CH
13:15-14:15	Lunch	

Note: Each 10 minute slot for clinical case discussion includes 5' case presentation and 5' Q&A / panel discussion